Key facts
- Ensocell’s last known valuation is $21.9M (Feb 2025).
- It has raised $16.3M; the latest was Early Stage VC ($13.1M) in Feb 2025.
- Notable investors include OMX Ventures, Sofinnova Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ensocell
- ·The full record, as it builds
Funding rounds
No funding rounds for Ensocell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ensocell
Developer of single-cell genomics technology intended to identify novel disease intervention points. The company specializes in utilizing AI-based computational tools and advanced cell models to discover novel therapeutics for autoimmune, inflammatory, and fibrotic diseases to decode the complexities of human disease biology, enabling researchers to provide regenerative therapies to fight diseases.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2023
- Employees
- 21
- Website
- ensocell.com/
- Ownership
- Privately Held (backing)
Ensocell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ensocell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ensocell in its N-PORT filings yet. We sweep new filings monthly.